title: Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.
abstract: Antituberculosis drug-induced hepatotoxicity is quite common. However, factors predicting its development are still controversial. The objective of the present study was to evaluate the role of certain factors (age and sex of the patient, alcoholism, chronic liver disease, hepatitis B virus carrier status, acetylator status, nutritional status and antituberculosis treatment (ATT) regimen) in predicting the development of ATT-induced hepatitis. In a case-control study, 60 consecutive patients with evidence of ATT-induced hepatitis were studied to assess the possible association of the above-mentioned factors with ATT-induced hepatitis. Body mass index was found to be significantly lower in ATT-induced hepatitis patients (17.2 +/- 2.7) than in controls (19.5 +/- 3.3) (p < 0.05). Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%). No significant differences were observed between the two groups with regard to the rest of the parameters.
authors.affiliation: Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi.
authors.forename: J
authors.initials: J
authors.lastname: Singh
authors.forename: A
authors.initials: A
authors.lastname: Arora
authors.forename: P K
authors.initials: PK
authors.lastname: Garg
authors.forename: V S
authors.initials: VS
authors.lastname: Thakur
authors.forename: J N
authors.initials: JN
authors.lastname: Pande
authors.forename: R K
authors.initials: RK
authors.lastname: Tandon
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D015992:Body Mass Index; D016022:Case-Control Studies; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009748:Nutrition Disorders / Q000150:complications*; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin